Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06139497
Other study ID # ANRS 0396 VIRAGE+
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 31, 2023
Est. completion date April 2024

Study information

Verified date November 2023
Source ANRS, Emerging Infectious Diseases
Contact Joseph Tegbe
Phone +225 7 57 77 77 00
Email joseph.tegbe@pac-ci.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this interventional study is to document the importance of HIV-related disabilities, notably the frequency / nature of functional limitations, neurocognitive impairments, and restrictions of social participation in adults living with HIV aged 40 and older. Participants will undergo a comprehensive set of cognitive and functional assessments, and approximately twenty particpants will be asked to participate in an anthropological survey conducted through structured interviews. Researchers will a group of people living with HIV and o reference group without HIV infection.


Description:

This is a mixed-methods study combining a cross-sectional study during which clinical evaluations, functional tests, and quantitative evaluations by questionnaire relating to disability (WHODAS, HDQ), depression (PHQ-9) will be conducted. and an anthropological survey. The study takes place in the Abobo district, Abidjan, in two health centers. The quantitative evaluation will concern 300 people living wiht HIV (PLHIV) receiving antiretroviral therapy and followed at the Avocatier health facility (FSU) and the El Rapha medical health centre (CMS), in the Abobo district, Abidjan. A comparison group of adults without HIV infection of similar sex and age distribution will also be included as a reference group (n = 150). The qualitative research will include around 20 PLHIV selected so that enough diversity is represented (sex, age, family situation). It will be based on conducting interviews to examine how the practice of physical activity is perceived culturally and socially and to determine the factors that may influence the implementation of this type of activity.


Recruitment information / eligibility

Status Recruiting
Enrollment 450
Est. completion date April 2024
Est. primary completion date April 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: Participants living with HIV: - Age =40 years - Documented HIV-infection - Combined ART for =12 months - Written consent to participate to the study Controls: - Age =40 years - Negative HIV test within the last 12 months; - Living in Abobo area - Written consent to participate to the study Exclusion Criteria: Participants living with HIV: - HIV infection with HIV-2 type only - Any clinical symptoms suggesting an acute infection - Any life-threatening pathology in the short term or any pathology not allowing participation in the study Controls: - Any clinical symptoms suggesting an acute infection - Any life-threatening pathology in the short term or any pathology not allowing participation in the study

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Quantitative research
A quantitative cross-sectional assessment of disability will be carried out.
Behavioral:
Qualitative survey
A qualitative survey will be conducted on the impact of functional limitations on participants' lives, on biographical reconstruction strategies and on PLWHIV's perception of the intervention and its implementation.

Locations

Country Name City State
Côte D'Ivoire Centre Médical Spécialisé El Rapha Abidjan
Côte D'Ivoire Formation semi urbaine (FSU) d'Abobo Avocatier Abidjan

Sponsors (3)

Lead Sponsor Collaborator
ANRS, Emerging Infectious Diseases Centre Population et Développement (CEPED/IRD), Programme PAC-CI

Country where clinical trial is conducted

Côte D'Ivoire, 

Outcome

Type Measure Description Time frame Safety issue
Primary Performance at the 6' step-up test Number of ascent-descent cycles counted over 6 minutes Day 0
Primary Performance at the 6' walking test Measures distance covered during a 6-minute period of rapid walking on a flat and hard surface Day 0
Primary Performances at the 5 stand-up and sit test Time required to perform 5 quick lifts from a seated position Day 0
Primary Performances at the Y balance Test Sum of distances reached in each direction (the best is chosen for each direction) divided by 3 x length of lower limb (standardization) and multiplied by 100 Day 0
Primary Grip strenght Force in kg measured with a dynamometer, twice per limb Day 0
Primary Short Physical Performance Battery (SPPB) score Score between 0 and 12, with 0 indicating the worst performance and 12 the highest degree of functionality Day 0
Primary Scores of the Neuroscreen app tests Score calculated by the application: that higher scores indicated better performance. Day 0
Primary WHO Disability Assessment Schedule - 2.0 (WHODAS) score The higher the calculated score, the more significant the encountered difficulties Day 0
Primary HIV Disability Questionnaire - short form (HDQ-SF) score The higher the calculated score, the more significant the encountered difficulties Day 0
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2